Loading clinical trials...
Loading clinical trials...
High Serum Ferritin Early in Pregnancy May Predict the Development of Gestational Diabetes Later.
This prospective study evaluates a target population of pregnant women at the time of pregnancy diagnosis to investigate the predictive value of serum ferritin (SF) levels for the later development of gestational diabetes mellitus (GDM). The intervention involves measuring early-pregnancy SF, transferrin, and hemoglobin levels, alongside HbA1c, and comparing these biomarkers between women who later develop GDM and those who remain normoglycemic. The primary outcome is to assess the success rate of this diagnostic regimen in identifying high-risk individuals, aiming to establish SF as a valuable early biomarker for GDM to enable timely interventions.
Age
21 - 40 years
Sex
FEMALE
Healthy Volunteers
No
Benha University
Banhā, Al Qalyoubia, Egypt
Start Date
December 5, 2022
Primary Completion Date
December 7, 2024
Completion Date
October 10, 2025
Last Updated
February 25, 2026
556
ACTUAL participants
Glycemic Markers
DIAGNOSTIC_TEST
Lead Sponsor
Zagazig University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07480161